China Oncology ›› 2023, Vol. 33 ›› Issue (1): 25-35.doi: 10.19401/j.cnki.1007-3639.2023.01.003
• Article • Previous Articles Next Articles
HU Keshu1,2(), LIU Wenfeng1,2, ZHANG Feng1,2, QUAN Bing1,2, YIN Xin1,2(
)
Received:
2022-09-08
Revised:
2022-10-08
Online:
2023-01-30
Published:
2023-02-13
Contact:
YIN Xin
Share article
CLC Number:
HU Keshu, LIU Wenfeng, ZHANG Feng, QUAN Bing, YIN Xin. Mechanism of LINC00601 in regulating sensitivity of hepatocellular carcinoma cells to oxaliplatin chemotherapy[J]. China Oncology, 2023, 33(1): 25-35.
Fig. 1
Oxaliplatin resistant cell line 97H-OXR and 3B-OXR, and the change of the LINC00601 expression The 97H-OXR and 3B-OXR cells were less sensitive to oxaliplatin treatment and their LINC00601 expression level was significantly increased. ***: P <0.001, compared with 97H; ****: P<0.000 1, compared with 3B."
Fig. 2
The effect of LINC00601 expression on the sensitivity to oxaliplatin of HCC cells A: The mRNA levels of LINC00601 in 97H-LNC and 97H-OXR-siLNC cells were validated by RTFQ-PCR. B: LINC00601 overexpression led to oxaliplatin resistance in 97H cells. C: LINC00601 knockdown resulted in the restore of sensitivity to oxaliplatin in 97H-OXR cells. D: The mRNA levels of LINC00601 in 3B-LNC and 3B-OXR-siLNC cells were validated by RTFQ-PCR. E: The sensitivity to oxaliplatin in 3B-OXR cells was reserved when LINC00601 was downregulated. *: P<0.05, compared with 3B-OXR-siNC; **: P<0.01, compared with 97H-OXR-siNC; ****: P <0.000 1, compared with 97H-control or 3B."
Fig. 3
The impact of LINC00601 on the apoptotic level of HCC cells after oxaliplatin treatment Oxaliplatin treatment induced significant apoptosis in non-oxaliplatin-resistant cells, however it had few influence on the apoptotic level of oxaliplatin-resistant cells. **: P<0.01; ***: P<0.001; ****: P<0.000 1."
Fig. 4
The impact of LINC00601 on the activation of caspase 3 protein HCC cells demonstrated upregulated caspase 3 activation level in an oxaliplatin dose-dependent manner. Control cells and OXR-siLNC cells showed significant caspase 3 activation after oxaliplatin treatment, while oxaliplatin-resistant cells had moderate changes of caspase 3 cleavage."
Fig. 5
The location of LINC00601 in the HCC cells and its impacts on the expression of GADD45A gene A: LINC00601 was found mainly located in the cytoplasm of HCC cells; B: RTFQ-PCR demonstrated that GADD45A mRNA level was downregulated in 97H-LNC cells; C: GADD45A level in different 97H cell lines; D: GADD45A mRNA level was illustrated by RTFQ-PCR in 3B cell lines; E: Western blot analysis was established to show the GADD45A expression level in different 3B cell lines. **: P<0.01, compared with 97H; ***: P<0.001, compared with 3B."
Fig. 6
The nuclear translocation process of GADD45A was interfered with LINC00601 expression A: GADD45A was marked by red fluorescence and was enriched in the cytoplasm of LINC00601 overexpression cells and oxaliplatin resistant cells, while its cytoplasm location was attenuated in control cells and oxaliplatin-resistant-siLNC cells. B: The location changes of GADD45A were further confirmed by Western blot."
Fig. 7
LINC00601 might bind to GADD45A LINC00601 RNA pull-down and RNA immunoprecipitation experiments demonstrated that LINC00601 mRNA could combine to GADD45A. A: LINC00601 RNA-pulldown revealed the combination between LINC00601 and GADD45A protein; B: LINC00601 expression was enriched in the RNA immunoprecipitation by anti-GADD45A."
[1] | 丁惠国, 屠红, 曲春枫, 等. 原发性肝癌的分层筛查与监测指南(2020版)[J]. 临床肝胆病杂志, 2021, 37(2): 286-295. |
DING H G, TU H, QU C F, et al. Guideline for stratified screening and surveillance of primary liver cancer (2020 edition)[J]. J Clin Hepatol, 2021, 37(2): 286-295. | |
[2] |
HU K S, LU S X, LI M, et al. A novel pre-treatment model predicting risk of developing refractoriness to transarterial chemoembolization in unresectable hepatocellular carcinoma[J]. J Cancer, 2020, 11(15): 4589-4596.
doi: 10.7150/jca.44847 pmid: 32489476 |
[3] |
XIE D Y, REN Z G, ZHOU J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights[J]. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463.
doi: 10.21037/hbsn-20-480 |
[4] |
SCHMITZ S U, GROTE P, HERRMANN B G. Mechanisms of long noncoding RNA function in development and disease[J]. Cell Mol Life Sci, 2016, 73(13): 2491-2509.
doi: 10.1007/s00018-016-2174-5 pmid: 27007508 |
[5] |
YIN X, ZHENG S S, ZHANG L, et al. Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells[J]. Gene, 2017, 596: 53-88.
doi: S0378-1119(16)30803-4 pmid: 27729273 |
[6] |
SHI X B, LI Y, SUN Y C, et al. Genome-wide analysis of lncRNAs, miRNAs, and mRNAs forming a prognostic scoring system in esophageal squamous cell carcinoma[J]. PeerJ, 2020, 8: e8368.
doi: 10.7717/peerj.8368 |
[7] |
HE Y K, YE Y F, TIAN W, et al. A novel lncRNA panel related to ferroptosis, tumor progression, and microenvironment is a robust prognostic indicator for glioma patients[J]. Front Cell Dev Biol, 2021, 9: 788451.
doi: 10.3389/fcell.2021.788451 |
[8] | WANG Y C, HU B H, ZHANG W W, et al. Linc00601 upregulation promotes hepatocellular carcinoma development by activating MAPK signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2020, 24(11): 6039-6045. |
[9] | RIDDELL I A. Cisplatin and oxaliplatin: our current understanding of their actions[J]. Met Ions Life Sci, 2018, 18: /books/9783110470734/9783110470734-007/9783110470734-007.xml. |
[10] | 曹宇, 倪娟, 曹能, 等. Gadd45蛋白家族在肿瘤发生、发展中的作用[J]. 肿瘤防治研究, 2019, 46(3): 271-274. |
CAO Y, NI J, CAO N, et al. Role of Gadd45 protein family in tumorigenesis and development[J]. Cancer Res Prev Treat, 2019, 46(3): 271-274. | |
[11] |
FENG X M, LIU H, ZHANG Z J, et al. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells[J]. J Exp Clin Cancer Res, 2017, 36(1): 123.
doi: 10.1186/s13046-017-0594-1 |
[12] |
LI J H, XIE X Y, ZHANG L, et al. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(13): 3970-3977.
doi: 10.3748/wjg.v21.i13.3970 |
[13] |
GAO S, ZHANG P J, GUO J H, et al. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients[J]. World J Gastroenterol, 2015, 21(36): 10443-10452.
doi: 10.3748/wjg.v21.i36.10443 |
[14] |
MARTINEZ-BALIBREA E, MARTÍNEZ-CARDÚS A, GINÉS A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance[J]. Mol Cancer Ther, 2015, 14(8): 1767-1776.
doi: 10.1158/1535-7163.MCT-14-0636 |
[15] |
LIM L J, WONG S Y S, HUANG F Y, et al. Roles and regulation of long noncoding RNAs in hepatocellular carcinoma[J]. Cancer Res, 2019, 79(20): 5131-5139.
doi: 10.1158/0008-5472.CAN-19-0255 pmid: 31337653 |
[16] |
HUANG H, CHEN J, DING C M, et al. LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363[J]. J Cell Mol Med, 2018, 22(6): 3238-3245.
doi: 10.1111/jcmm.13605 pmid: 29602203 |
[17] |
HU H Q, YANG L, LI L J, et al. Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis[J]. Biochem Biophys Res Commun, 2018, 503(4): 2400-2406.
doi: 10.1016/j.bbrc.2018.06.168 |
[18] |
DONG S B, FU Y, YANG K B, et al. Linc01559 served as a potential oncogene and promoted resistance of hepatocellular carcinoma to oxaliplatin by directly sponging miR-6783-3p[J]. Anticancer Agents Med Chem, 2021, 21(2): 278-286.
doi: 10.2174/1871520620666200721122317 |
[19] | HUANG G L, LI L, LIANG C Y, et al. Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR-138-5p and activation of AKT/mTOR signaling pathway[J]. Pharmacol Res Perspect, 2021, 9(1): e00720. |
[20] |
XIONG H, NI Z, HE J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells[J]. Oncogene, 2017, 36(25): 3528-3540.
doi: 10.1038/onc.2016.521 pmid: 28166203 |
[21] |
ZHU N, SHAO Y, XU L, et al. Gadd45-alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cells[J]. Mol Biol Rep, 2009, 36(8): 2075-2085.
doi: 10.1007/s11033-008-9419-9 pmid: 19048389 |
[22] |
TONG T, JI J F, JIN S Q, et al. Gadd45a expression induces Bim dissociation from the cytoskeleton and translocation to mitochondria[J]. Mol Cell Biol, 2005, 25(11): 4488-4500.
pmid: 15899854 |
[23] |
DU K G, LU F, XIE C Z, et al. Toxoplasma gondii infection induces cell apoptosis via multiple pathways revealed by transcriptome analysis[J]. J Zhejiang Univ Sci B, 2022, 23(4): 315-327.
doi: 10.1631/jzus.B2100877 |
[24] | JANG H J, YANG J H, HONG E, et al. Chelidonine induces apoptosis via GADD45a-p53 regulation in human pancreatic cancer cells[J]. Integr Cancer Ther, 2021, 20: 15347354211006191. |
[25] |
WANG X, ZOU F, ZHONG J T, et al. Secretory clusterin mediates oxaliplatin resistance via the Gadd45a/PI3K/Akt signaling pathway in hepatocellular carcinoma[J]. J Cancer, 2018, 9(8): 1403-1413.
doi: 10.7150/jca.23849 pmid: 29721050 |
[1] | WEN Ziqiang, LAN Junliang, ZHOU Bo, XU Qiwei. PARP1 promotes the progression of hepatocellular carcinoma by regulating expression of POU2F2 [J]. China Oncology, 2024, 34(9): 848-856. |
[2] | YAN Yan, ZHOU Liqing, XIA Jianhong, MA Tingting. TCF7 transcriptional activation of MACC1 regulates aerobic glycolysis and promotes oxaliplatin resistance in rectal cancer [J]. China Oncology, 2024, 34(8): 715-725. |
[3] | XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan. Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma [J]. China Oncology, 2024, 34(8): 726-733. |
[4] | CAO Fei, YU Wenhao, TANG Xiaonan, MA Zidong, CHANG Tingmin, GONG Yabin, LIAO Mingjuan, KANG Xiaohong. Mechanism of LINC01410 promoting proliferation and migration in esophageal squamous cell carcinoma [J]. China Oncology, 2024, 34(8): 753-762. |
[5] | Cancer Assessment Society of China Anti-Cancer Association, Cancer Pain Society of Fujian Anti-Cancer Association. Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition) [J]. China Oncology, 2024, 34(8): 785-805. |
[6] | YE Junling, ZHENG Xiaoying, GUO Xinjian, CHEN Ruihui, YANG Liu, GOU Xiaodan, JIANG Hanmei. A study on mechanism of lncRNA-mediated SNHG5/miR-26a-5p/MTDH signal axis promoting metastasis of colorectal cancer [J]. China Oncology, 2023, 33(7): 673-685. |
[7] | ZHAO Haichao, GAO Qiang. Progress in research, diagnosis, and treatment of hepatocellular carcinoma in 2022 [J]. China Oncology, 2023, 33(4): 315-326. |
[8] | CHEN Anli, SHEN Haoyuan, YANG Shixiong, DENG Chunyan, HU Chaohua, LIU Hanzhong, WANG Shu, QIAN Fang. Predictive value of plasma long non-coding RNA H19 in neoadjuvant therapy for breast cancer [J]. China Oncology, 2022, 32(8): 727-735. |
[9] | LIAO Xinghe, LIU Zhantao, LIU Minghui. Glioma stem cell-derived exosomal lncRNA HOXA-AS2 promoted proliferation, migration, invasion and stemness in glioma [J]. China Oncology, 2022, 32(12): 1218-1228. |
[10] | CHENG Yicai, DU Zhenhua, FAN Zhijuan, FENG Lan, CAO Pengbo, ZHOU Gangqiao. Plasma exosomal CD48 protein as a candidate diagnostic biomarker for hepatocellular carcinoma [J]. China Oncology, 2022, 32(11): 1074-1083. |
[11] | GUO Tao, SONG Ning, SUN Yuqi, TIAN Jiaqi, TANG Jie, SUN Rongqi, JIANG Yingying. Effect of long non-coding RNA LINC00671 on biological behavior of hepatocellular carcinoma and its mechanism [J]. China Oncology, 2022, 32(10): 990-999. |
[12] | JIN Youping, LI Luying, ZHOU Ping. A study on the role of long non-coding RNA STMN1P2 in breast cancer and its mechanism [J]. China Oncology, 2021, 31(7): 596-604. |
[13] | ZHENG Peiming , LI Junmeng , ZHANG Peng , GAO Lan . Exosomal transfer of macrophage-derived miR-223 confers oxaliplatin resistance in gastric cancer [J]. China Oncology, 2021, 31(5): 368-378. |
[14] | XIAO Feng , XIAO Jingwen , SHAO Jianguo , CHEN Liyan , GU Chunyan . The expression of programmed death 1 in tumor-infiltrating lymphocytes of hepatocellular carcinoma and its correlation with prognosis [J]. China Oncology, 2021, 31(5): 419-427. |
[15] | NIU Na, LIN Yansong. Application and research progress of selective internal radiation therapy with 90 Y microspheres in hepatocellular carcinoma [J]. China Oncology, 2021, 31(5): 428-434. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd